Clinical trials: Non Small Cell Lung Carcinoma NSCLC, open to volunteers
- Condition Non Small Cell Lung Carcinoma NSCLC
- Status Open to volunteers
- Accepts healthy volunteers yes
Malignant Solid Tumors, Clear Cell Renal Cell Carcinoma
CAIX-targeted PET/CT in Solid Tumors
Tumor hypoxic microenvironment plays an important role in the initiation and progression of solid tumors, as well as tumor invasion, metastasis, and treatment resistance.
- Conditions
- Malignant Solid Tumors, Clear Cell Renal Cell Carcinoma, Lung Cancer (NSCLC), Breast Cancer
- Trial name
- CAIX-PET (NCT07833085)
- Testing
- 68Ga-CAIX
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Zhongnan Hospital
Bladder Cancer, Glioma
Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer
The objective of this study is to assess two novel positron emission tomography (PET) radiotracers, [64Cu]CM500 and [68Ga]CM500, for Positron Emission Tomography-Magnetic Resonance Imaging (PET-MR) and Positron Emission…
- Conditions
- Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer
- Trial name
- NCT07781852
- Testing
- [64Cu]CM500, [68Ga]CM500, PET/MR
- Where
- 3 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Lumina Pharmaceuticals Inc
Non-communicable Diseases (NCD), Neoplams
Health for Hungary (H4H) - Longitudinal Collection of Blood Samples and Corresponding Data
The Health for Hungary (H4H) study collects blood samples and corresponding health data to investigate healthy aging and health-to-disease transitions in middle-aged and elderly participants.
- Conditions
- Non-communicable Diseases (NCD), Neoplams, Cancer, Lung Cancer (NSCLC)
- Trial name
- H4H (NCT07743021)
- Where
- 33 sites in Hungary
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Center for Molecular Fingerprinting Research Nonprofit LLC
Lung Cancer (NSCLC), Lung Cancer (Non-Small Cell)
Immune Response to Immunotherapy in Lung Cancer: Study of Sputum and Blood Samples
Lung cancer is the leading cause of cancer-related death worldwide, with nearly 2.48 million cases and 1.8 million deaths in 2022.
- Trial name
- RICEPS-2 (NCT07163507)
- Testing
- Blood sample, sputum sample
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University Hospital, Tours
Brest Cancer, Lung Cancer (NSCLC)
The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling
The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients.
- Conditions
- Brest Cancer, Lung Cancer (NSCLC), Pancreatic Cancer, Adult, Prostate Cancers
- Trial name
- CCANED-CIPHER (NCT06717295)
- Testing
- DiNanoQ: A multi-cancer early detection (MCED) blood test, DiNanoTrack: Therapeutic Response Monitoring Blood Test
- Where
- 4 sites in Argentina, Nigeria and 1 more
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Javier Toledo
COPD, Lung Cancer (NSCLC)
Tumors and Respiratory System Diseases Due to Air Pollution: New Biomarkers of Exposure and Effects
This study aims to examine the exposure to atmospheric pollutants in a group of non-smoking patients suffering from lung cancer, chronic obstructive pulmonary disease (COPD), and leukemia.
- Conditions
- COPD, Lung Cancer (NSCLC), Leukemia
- Trial name
- RECAP (NCT06800586)
- Where
- 3 sites in Italy
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
NSCLC Stage IIIB, NSCLC Stage IIIC
Clinical Outcomes of Tislelizumab Combined With Chemotherapy as Induction Therapy in Stage III (cTNM-IIIB/IIIC) NSCLC
This is an observational study evaluating the clinical characteristics, treatment patterns, and clinical outcomes in Stage III (cTNM-IIIB/IIIC) Non-Small Cell Lung Cancer.Patients meeting inclusion and exclusion criteria were…
- Trial name
- NCT06829641
- Testing
- Tislelizumab Combined with Chemotherapy,
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- West China Hospital
NSCLC (advanced Non-small Cell Lung Cancer)
Pharmacokinetic Study of HS-10365 Capsule in Subjects with Hepatic Impairment and Normal Hepatic Function
This study will be conducted in subjects with moderate Hepatic Impairment, mild hepatic Impairment and normal hepatic function. The study will be conducted in two stages.
- Trial name
- NCT06823258
- Testing
- HS-10365
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.